Kiniksa Pharmaceuticals | 8-K: FY2026 Q2 Revenue Beats Estimate at USD 243.6 M

Revenue: As of FY2026 Q2, the actual value is USD 243.6 M, beating the estimate of USD 226.46 M.

EPS: As of FY2026 Q2, the actual value is USD 0.3.

EBIT: As of FY2026 Q2, the actual value is USD 31.15 M.

Second Quarter 2026 Financial Performance

Revenue

Kiniksa Pharmaceuticals International, plc reported total revenue of $243.6 million for the second quarter of 2026, an increase from $156.8 million in the second quarter of 2025. Net product revenue from ARCALYST was $243.6 million, representing approximately 55% year-over-year growth.

Operating Expenses

Total operating expenses for the second quarter of 2026 were $216.4 million, compared to $136.6 million for the second quarter of 2025. This included Cost of Goods Sold (COGS) expenses of $23.6 million (up from $18.6 million in Q2 2025), Collaboration expenses of $88.1 million (up from $52.4 million in Q2 2025), Research and Development (R&D) expenses of $40.9 million (up from $18.8 million in Q2 2025), and Selling, General, and Administrative (SG&A) expenses of $63.9 million (up from $46.9 million in Q2 2025). Total operating expenses included $11.6 million in non-cash, share-based compensation expense for Q2 2026, compared to $8.9 million for Q2 2025.

Profitability

Income from operations was $27.194 million for Q2 2026, increasing from $20.160 million in Q2 2025. Other income, net, was $3.951 million in Q2 2026, up from $2.717 million in Q2 2025. Income before income taxes stood at $31.145 million in Q2 2026, compared to $22.877 million in Q2 2025. The provision for income taxes was - $5.713 million in Q2 2026, versus - $5.045 million in Q2 2025. Net income for the second quarter of 2026 was $25.4 million, an increase from $17.8 million for the second quarter of 2025.

Balance Sheet Highlights (as of June 30, 2026)

Cash and Investments

Kiniksa Pharmaceuticals International, plc held $525.9 million in cash, cash equivalents, and short-term investments, with no debt, as of June 30, 2026. This compares to $414.074 million as of December 31, 2025.

Working Capital and Assets

Working capital was $497.386 million as of June 30, 2026, up from $387.993 million at December 31, 2025. Total assets were $896.110 million as of June 30, 2026, compared to $763.633 million at December 31, 2025.

Equity

The accumulated deficit was - $414.114 million as of June 30, 2026, an improvement from - $462.138 million at December 31, 2025. Total shareholders’ equity stood at $654.149 million as of June 30, 2026, increasing from $567.606 million at December 31, 2025.

Operational Metrics

Approximately 21% of the 14,000 multiple-recurrence patients were actively on ARCALYST treatment as of the end of the second quarter of 2026. Since launch, more than 5,000 prescribers have written ARCALYST prescriptions for recurrent pericarditis. The average total duration of ARCALYST therapy in recurrent pericarditis was approximately 3 years as of the end of Q2 2026.

Outlook and Guidance

Kiniksa Pharmaceuticals International, plc increased its 2026 ARCALYST net product revenue guidance to between $980 million and $995 million, up from the prior guidance of $930 million to $945 million. The company anticipates its current operating plan to remain cash flow positive on an annual basis. KPL-387 is expected to be commercialized in the ²⁰²⁸⁄₂₀₂₉ timeframe, and a Phase 1 clinical trial for KPL-1161 is projected to initiate by the end of 2026.